CompletedInterventional · Phase 3NCT03283085 ↗A Phase 3 Long-term Safety Extension Study of SHP647 in Subjects With Moderate to Severe Ulcerative Colitis or Crohn's Disease (AIDA)
CompletedInterventional · Phase 2/3NCT03398148 ↗A Multicenter, Randomized, Double-Blind, Placebo Controlled Induction Study to Evaluate the Efficacy and Safety of Risankizumab in Subjects With Moderately to Severely Active Ulcerative ColitisAliza B SolomonPIInterventionDrug: risankizumab IV · Drug: placebo for risankizumab · Drug: risankizumab SCDatesMar 2018 – Nov 2022· Results postedSponsorAbbVie Inc.Ulcerative Colitis (UC)
CompletedInterventional · Phase 2NCT03558152 ↗A Phase II, Randomized, Parallel-Group, Double-Blind, Double-Dummy, Placebo-Controlled, Multicenter Study To Evaluate the Efficacy, Safety, and Pharmacokinetics of UTTR1147A Compared With Placebo and Compared With Vedolizumab in Patients With Moderate to Severe Ulcerative ColitisRandy LongmanPIInterventionDrug: UTTR1147A · Drug: UTTR1147A Placebo · Drug: Vedolizumab · Drug: Vedolizumab PlaceboDatesOct 2018 – Dec 2021· Results postedSponsorGenentech, Inc.Ulcerative Colitis
CompletedInterventional · Phase 2NCT03998488 ↗A Randomized, Placebo-controlled Clinical Trial Examining the Efficacy of Fecal Microbiota Transplantation (FMT) and Subsequent Dietary Fiber in Patients With Moderate Ulcerative ColitisRandy LongmanPIInterventionDrug: Fecal Microbiota Transplantation · Dietary supplement: Psyllium Husk PowderDatesJan 2020 – Jun 2023· Results postedSponsorWeill Medical College of Cornell UniversityUlcerative ColitisInflammatory Bowel Diseases
CompletedInterventional · Phase 4NCT04259138 ↗VERDICT: In actiVE Ulcerative Colitis, a RanDomIzed Controlled Trial for Determination of the Optimal Treatment TargetDana Jeremy LukinPIInterventionBiological: Treatment Algorithm A · Biological: Treatment Algorithm B · Biological: Treatment Algorithm CDatesFeb 2020 – Apr 2026SponsorAlimentiv Inc.Colitis, Ulcerative
CompletedInterventional · Not applicableNCT04672161 ↗Education Intervention on Vaccination Adherence Among IBD Patients at Weill Cornell Medical CenterDana Jeremy LukinPIInterventionOther: Vaccine EducationDatesFeb 2021 – Jun 2022SponsorWeill Medical College of Cornell UniversityCrohn Disease (CD)Ulcerative Colitis (UC)Indeterminate Colitis
CompletedInterventional · Phase 2NCT04996797 ↗A Phase 2, Multi-Center, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Induction Therapy With PRA023 in Subjects With Moderately to Severely Active Ulcerative ColitisRandy LongmanPIInterventionDrug: Tulisokibart · Device: Companion Diagnostic (CDx) Testing · Other: PlaceboDatesJul 2021 – Jun 2023· Results postedSponsorPrometheus Biosciences, IncUlcerative Colitis